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ABSTRACT
Given a better quality of life and extended life expectancy in patients with immune suppression, the number 
of immunocompromised travellers is constantly growing. The aim of the article is to discuss travel-related 
health problems in immunocompromised patients, their most common destinations and reasons to travel, 
as well as complications associated with travel to regions with harsh environmental conditions. The artic-
le focuses on selected groups of immunocompromised travellers (ICTs), i.e., cancer patients, transplant 
patients receiving immunosuppressant agents, splenectomised patients and HIV-infected individuals. The 
most common infections and complications, including traveller’s diarrhoea, vector-borne diseases (yellow 
fever, malaria, leishmaniasis, dengue, chikungunya), respiratory infections (including tuberculosis), and 
dermatoses were taken into account. Preventive measures dedicated to ICTs (pre-travel consultation, vac-
cinations, malaria chemoprophylaxis, prevention during travelling) have been also characterised. 
(Int Marit Health 2017; 68, 4: 229–237)
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INTRODUCTION
The number of domestic and international travellers 
is growing every year. According to the World Tourism Or-
ganisation, international tourist arrivals reached a total of 
1,235 billion in 2016 [1]. The growth in international tourist 
movement has been estimated at 4% and more in 6 con-
secutive years since 2010. This fact is especially important 
as a large group of travellers chose as their destinations 
Asia and Africa, where travel-related morbidity is high [2]. 
According to Patel et al. [3], travelling to a wide range of 
destinations has become more available to increasingly 
diverse populations of travellers.
At the same time, the number of immunocompromised 
patients is constantly growing. This large and varied group of 
patients include those with primary immunodeficiency, ma-
lignancy or human immunodeficiency virus (HIV) infection, 
as well as those receiving iatrogenic immunosuppression af-
ter organ or stem transplantation, rheumatologic disorders 
and autoimmune diseases [3]. There are a number of other 
medical conditions, like diabetes, pregnancy, skin and mu-
cosal disorders, reduced gastrointestinal acid barrier, car-
diovascular prostheses and even advanced age (> 60) [4], 
as well as alcoholism or renal failure [5], which may cause 
immune deficiency and put these patients at a higher risk 
of infection, especially while travelling. It was estimated that 
the number of immunocompromised patients increased 
both in industrialised and developing countries [6]. This 
situation was caused, amongst others, by a rapid spread 
of HIV infections, more intense malignancy treatments (in-
cluding bone marrow and solid organ transplantations) 
and extended life expectancy of patients with chronic dis-
eases and malignancies in general. The widespread use of 
new immunosuppressive therapies in transplant patients, 
a growing number of malignancies as well as inflammatory 
and autoimmune diseases resulted in an increased number 
of immunocompromised patients [7, 8]. Given the higher 
quality of life and longer life expectancy of those patients, 
there are now more immunocompromised people interested 
in travelling.
As Dekkiche et al. [7] estimate, there is very little data in 
medical literature about travelling with immune suppression. 
Studies regarding the frequency and travel patterns amongst 
immunocompromised travellers (ICTs) are scarce [2]. 
Also, information about the real risk of infections in ICTs 
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compared to other travellers is limited [9]. The studies that 
have been performed so far seem to be very specific or, quite 
the opposite, very broad. Also, the study findings are fre-
quently mutually exclusive [7]. However, as Askling et al. [2] 
pointed out, immunocompromised patients do travel and 
they are at a much higher risk of travel-related infections and 
complications than healthy travellers. In addition, despite 
their medical condition, they do not always seek pre-travel 
counselling.
EPIDEMIOLOGY
Owing to better therapeutic options for immunocom-
promised patients, their general health is improving [7]. As 
they live longer and the quality of their life is incomparably 
better than in the past [9], they do travel more. According to 
Dekkiche et al. [7], chronic immune suppression is not a con-
traindication for travelling, even to tropical destinations. 
Three percent of 13,235 travels included in the American 
study mentioned by LaRocque et al. [10] were performed 
by travellers with immunocompromising conditions. In the 
study performed by Hochberg et al. [11], 23.3% of 15,440 
travellers seeking pre-travel care were considered immu-
nocompromised.
Destinations chosen by that group of travellers are also 
extremely important. In the study by LaRocque et al. [10], 
98% of ICTs chose low-income or low-middle-income coun-
tries as their stamping ground. In the study by Uslan et al. 
[12], 26.7% of solid organ recipients travelled outside the 
United States and Canada and 16.2% of these travellers 
chose Central or South America, Asia, Africa or the Middle 
East as their destinations. In the American study of 267 
transplant recipients, 36% of them travelled outside the 
United States and Canada [13]. In the study performed by 
Dekkiche et al. [7], 26.8% of ICTs chose South-East Asia, 
17.2% travelled to South Asia and 15.2% to West Africa. The 
study performed by Allen and Patel [14] revealed that 53% 
ICTs chose Sub-Saharan Africa as their destination. Patel 
et al. [3] underline the importance of taking into account 
the specific destination chosen by ICTs — first of all, if it is 
rural or urban, and next, to which region or city specifically 
they are heading to. That data might be essential, either 
for pre-travel consultation or to determine travel-related 
morbidity.
The reason to travel is also important while discussing 
travel-related diseases. Travellers visiting friends and rela-
tives (VFRs) are at a higher risk of systemic febrile diseases, 
parasitic infections, sexually transmitted diseases, tuber-
culosis as well as respiratory syndromes [15]. In the study 
performed by Dekkiche et al. [7], 91.4% of ICTs cited tourism 
or VFRs as the reason to travel. Another study reported that 
43% of the ICTs went abroad for tourism purposes and 
22% to visit friends and relatives [14]. According to Mikati 
et al. [16], immunocompromised VFRs are at a  ‘double 
epidemiological risk’ of travel-related infections due to their 
immune suppression and behavioural and environmental 
risk that is inevitable while coexisting with local population 
and acquiring local habits.
As estimated by Askling et al. [2], ICTs are a very het-
erogeneous group. The Canadian Committee to Advise on 
Tropical Medicine and Travel (CATMAT) in its Advisory Com-
mittee Statement estimates the most important areas of 
interaction between immunosuppression and travel [5]. First 
of all, ICTs have an increased susceptibility to infections. 
Studies concerning infections appearing in ICTs showed that 
in this specific group of travellers the risk of complications 
is higher, as well as the rates of hospitalisation when an 
infection occurred [5]. It is also important to remember 
that not only their risk of deterioration or flare of underly-
ing medical condition is increased, but also they are more 
prone to become ill due to travel-related infections [14]. 
The second important issue is connected with concerns 
about vaccinations — their safety and potentially decreased 
efficacy [5]. Live vaccines are associated with an elevated 
risk of vaccine-related diseases. Also, the traveller’s immune 
system may not be capable of creating an efficient antibody 
response to a vaccination [3]. Finally, there are concerns 
about the use of drugs for the underlying conditions, par-
ticularly their supply while travelling as well as the potential 
interactions with other drugs [5]. It is especially important 
while considering malaria chemoprophylaxis.
Different type of immune suppression may be associ-
ated with a specific disease risk [5]. In the group of ICTs, 
there are different degrees of risk of infections, varying 
levels of vaccine immunogenicity as well as a varying risk 
of vaccine-related complications [2]. Immunosuppression 
leads to a  higher risk of opportunistic travel-related dis-
eases; however, that risk much depends on the nature 
of immunocompromise [17]. For example, corticosteroids 
affect cell mediated immunity, but not necessarily humoral 
immunity. Therefore, a patient under corticosteroid therapy 
may not be a candidate for a pneumococcal vaccination. At 
the same time, splenectomy may affect humoral immunity 
rather than cell mediated immunity, which may lead to 
a higher risk of infection with encapsulated organisms; this 
may be an indication for a pneumococcal vaccination [17]. 
Because of those differences every immunocompromised 
traveller’s case should be treated individually. The degree 
of immunodeficiency is difficult to measure. In case of 
HIV-infected travellers their immunodeficiency can be de-
fined by measuring CD4 lymphocytes. In other forms of 
immunosuppression there has been no specified measure 
to quantify it so far [5]. 
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GROUPS OF IMMUNOCOMPROMISED 
TRAVELLERS 
PATIENTS WITh CANCER
According to Mikati et al. [16], the prognosis for cancer 
patients has improved and so has the quality of their life 
and their ability to travel. Imunnosuppression in a cancer 
patient may be caused by malignancy itself or the treatment 
received. The impact of malignancy on the immunological 
system depends on the type of cancer and the treatment 
performed [5]. In the majority of cases, the time of the high-
est immune suppression is immediately after chemotherapy 
and/or radiotherapy [5]. Cancer patients are at a higher risk 
of infections during this time, especially during neutropenia, 
and most patients should be discouraged from travelling 
during that period [9]. According to Centres for Disease Con-
trol and Prevention mentioned by Mikati et al. [16], travellers 
are considered immunocompromised for 3 months after 
their last chemotherapy. However, cancer therapy varies be-
tween patients, especially in the duration and type of treat-
ment. In general, patients treated for solid tumours have 
usually milder and shorter immune suppression, in com-
parison to patients with haematological malignancies [16]. 
There are some specific malignancies, such as Hod-
gkin’s lymphoma in particular (and also non-Hodgkin’s lym-
phoma) that are associated with a  significant decrease 
of cell-mediated immunity which can even last after the 
termination of treatment. Also, some treatments, such as 
purine analogues therapy, may be connected with a major 
decrease of cell-mediated immunity. At the same time, mul-
tiple myeloma and B-cell chronic lymphocytic leukaemia are 
associated with major suppression of humoral immunity and 
higher susceptibility to some specific infections, especially 
with encapsulated organisms. However, there are some 
long-term hormonal cancer treatments, involving for exam-
ple tamoxifen, that may not significantly affect the function 
of the immune system [5]. It is essential for the physician 
to get to know the detailed history of a traveller’s disease 
and the course of their treatment while counselling them 
during a pre-travel consultation.
TRANSPLANT PATIENTS
Due to modern surgical techniques and effective im-
munosuppressive therapy, transplant patients lives have 
improved and so has their ability to travel [18]. Immuno-
suppression in solid transplant recipients varies not only 
depending on the transplanted organ [5], but also on the 
time after transplantation, the dose of immunosuppressants 
and the presence of acute or chronic rejection episode that 
may be associated with elevated doses of immunosuppres-
sive agents [19]. According to Boggild et al. [13], the risk 
is higher in heart-lung, lung, liver or pancreas transplant 
recipients and lower after kidney and heart transplants. 
A small intestine transplant also requires stronger immune 
suppression [5]. The period of the first 6 months is the time 
of the highest decrease of immune competence [5, 13]. 
Infections during the first month after the transplant are 
mostly related to the surgery and the stay in the intensive 
care unit. The period from 2 to 6 months after the transplant 
is associated with the highest level of immune suppression 
and due to this fact the majority of opportunistic infections, 
such as Herpes virus infections (especially Cytomegalovirus) 
or Pneumocystis jirovecii pneumonia, are diagnosed during 
this period [9]. From 6 to 12 months after transplantation 
the risk of infections decreases [9], if the doses of immu-
nosuppressants are at their minimum [13]. For this reason, 
transplant recipients should be discouraged from travelling 
during the first year after the transplant [9]. However, the 
immune suppression persists during the whole time of 
treatment, which means during the whole lifetime. There 
are some specific situations, such as chronic rejection, per-
sistent organ dysfunction or chronic cytomegalovirus (CMV) 
infection that are associated with a higher immune suppres-
sion [5]. Transplant recipients should also be encouraged 
to consider avoiding destinations where high-level medical 
care is not available [17]. A patient after a transplant is at 
a higher risk of not only acquiring travel-related diseases, 
but also reactivating his/her latent infections; therefore 
the access to high-level medical care is essential [12]. It 
is also crucial for the patients under immune suppressant 
therapy to remember about adequate drug supply while 
travelling, and also taking into account time changes while 
travelling across time zones. Due to their increased T-cell 
immunity, transplant recipients, should be approached like 
HIV-positive patients with CD4 count below 100. The risk 
of intracellular infection with organisms such as Salmonel-
la, Listeria and other fungal and mycobacterial infections 
may be increased [17]. In the case of stem cell transplant 
patients, the level of their immune suppression depends 
on chemotherapeutic agents used prior to the transplant, 
the type of the transplant — autologous (auto-HSCT) or 
allogenic (allo-HSCT) and the degree of graft vs. host dis-
ease (GVHD) that may be treated with immune suppressive 
drugs [19]. Both Auto-HSCT and allo-HSCT recipients suffer 
from impaired immune system functioning during the early 
post-transplant period, meaning first weeks to months after 
the transplant [19] and they are at a higher risk, especial-
ly of bacterial and fungal infections [9]. Graft-versus-host 
disease may put the patients at increased risk of viral in-
fections, especially CMV, BK virus and adenovirus [20]. Ac-
cording to McCarthy and Mileno, allo-HSCT recipients should 
be approached like functionally asplenic patients during 
2 years after the transplant [21]. However, even though 
HSCT recipients are more immunocompromised than pa-
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tients after solid organ transplant during the early post-trans-
plant period [19], their immune system gets back to normal 
functioning after around 2 years after the transplant if they 
cease the immune suppressant treatment and they do not 
suffer from graft-versus-host disease [5, 9]. 
hIV-INFECTED PATIENTS
HIV pandemic seems to be the major cause of immuno-
suppression worldwide [6]. Antiretroviral therapy (HAART) 
changed perspectives for HIV-positive patients [22], also 
allowing them to travel internationally [23]. HIV-positive pa-
tients’ immune deficiency depends on the function of periph-
eral CD4 T-cells, nadir CD4 T-cell count, the presence or ab-
sence of HAART therapy and whether the HIV viral load has 
decreased and immunological recovery has occurred [19]. 
The degree of immunosuppression in HIV-infected pa-
tients may be evaluated using a CD4 cell count. Patients 
with over 500 cells/mm may be considered as travellers 
with normal immune function. Travellers with 200–500 
cells/mm should be approached like patients with mild to 
moderate suppression. The count below 200 cells/mm is 
related to relatively severe immunosuppression. Patients 
with CD4 count below 50/mm are considered profoundly 
immunosupressed [5]. According to a  study by Sherrard 
and McCarthy [24], endemic-born travellers with HIV infec-
tions, i.e. patients coming from countries where infectious 
travel-related diseases are endemic, are staying abroad for 
longer periods and also they visit their friends and relatives 
more often. They also visit malaria-endemic regions more 
frequently than non-endemic born patients. In the group of 
endemic-born HIV-infected patients, the prevalence of trav-
el-related infections was found to be higher. Also, the course 
of travel-acquired infections may be more severe and they 
may be more difficult to treat in endemic-born patients [24]. 
It is important for the patients under HAART therapy to 
ensure the adequate drug supply and drug storage during 
their trip. It is recommended to place all medications in the 
hand-carried luggage to minimize the risk of losing them, 
as they may not be available everywhere in the world [22]. 
Another important problem is the risk of a travel ban or dis-
crimination against HIV-infected travellers [5]. There are many 
countries with entry restrictions for HIV-positive travellers, 
especially those travellers willing to stay in a given country for 
a longer period, e.g. applying for a residence or a work visa. 
There are also countries with restrictions for short-term trav-
ellers or even countries with policies of deporting HIV-infected 
people. The list of the countries changes continuously and 
travel-medicine specialists should inform their patients about 
the possibility of such restrictions [22]. There are databases 
available on the Internet where travellers can verify the exis-
tence of such restrictions in the country of destination prior 
to travel to avoid difficulties on the border [25]. 
PATIENTS UNDER IMMUNOSUPPRESSANT  
ThERAPIES
There is a huge group of patients being treated for au-
toimmune diseases and rheumatological disorders, such as 
rheumatic arthritis, inflammatory bowel diseases, psoriasis, 
sarcoidosis, systemic lupus erythematosus, vasculitides and 
many others [2, 14]. These conditions may have immunomod-
ulatory effect themselves, but most importantly, therapies 
used in these diseases, either classical immune suppressant 
agents or new biological drugs do impair the functioning of 
the immune system [14]. Drugs-induced immune suppression 
differs, especially according to the type, dose and reason 
for using the medication. All the components of the immune 
system are functionally impaired by glucocorticoids, repre-
sented most significantly by prednisone [3, 19]. Prednisone 
seems to be the most commonly used immunosuppresive 
drug. It is prescribed in inflammatory, auto-immunological 
diseases and many other medical conditions. According to 
Askling et al. [2], from 1% to 2% of adult population use 
it. It has a very wide range of effects and it predisposes to 
bacterial and fungal infections [3]. Patients whose therapy 
lasts longer than 2 weeks and taking a dose equivalent to 
over 20 mg of prednisone a day should be approached like 
patients with HIV infection with a CD4 cell count below 200 
cells/mm, which means that their immune suppression can be 
considered as relatively severe [5]. There are other widely used 
immunosuppresive agents. The most important are azathio-
prine, a purine analogue; methotrexate, structural analogue 
of folic acid; cyclosporine, a cyclic peptide; and tacrolimus, an 
agent inhibiting T-cell activation [2]. Biological agents start to 
play an important role in treating autoimmune and chronic 
inflammatory diseases. They are produced  to target a spe-
cific element of immune system, like B-cells, interleukins or 
tumour necrosis factor alpha. The most commonly used drugs 
from that group of medications are anti-tumour necrosis fac-
tor (TNF)-alpha agents [2]. Travellers taking antimetabolites, 
chemotherapeutics, alkylating agents, immunomodulators or 
TNF blockers are generally considered as patients with severe 
immune compromise [3]. The majority of available data about 
travellers under biological therapy is about anti-TNF-alpha 
agents. Patients under that kind of therapy may be at a higher 
risk of developing skin infections. In the Dutch study, travellers 
with compromised immunity system were found to be at an 
increased risk of skin infections, fatigue and abdominal pain. 
There were also cases of cutaneous leishmaniasis in this 
group of patients [9]. Also, travellers taking TNF-blockers are 
more prone to re-activate a tuberculosis infection as well as 
to develop a primary infection [5]. 
SPLENECTOMISED PATIENTS 
Travellers after splenectomy are prone to infections with 
encapsulated organisms [5, 9]. The major risk is Streptococ-
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cus pneumoniae infection; however, infections caused by 
Neisseria meningitidis, Haemophilus influenzae and Capno-
cytophaga are also common. The risk is at its highest level 
during the first two years after the splenectomy. However, the 
elevated risk of these infections remains for the lifetime [5]. 
It is essential for splenectomised patients to receive ade-
quate vaccinations prior to travel. Asplenic patients should 
have a supply of antibiotics while travelling to enable quick 
empirical treatment of febrile diseases which may be caused 
by encapsulated organisms [9, 17]. In a study on the group 
of Danish children it was proved that a  combination of 
pneumococcal vaccine and early penicillin therapy in febrile 
diseases reduced the risk of fatal sepsis [5]. It is important 
to remember that a risk of acquiring infections is associ-
ated with underlying conditions in asplenic patients. It is 
increased in patients with haematological diseases or those 
with suboptimal immunisation. Splenectomised patients are 
at a higher risk of developing severe malaria as their ability 
to clear Plasmodium parasites is impaired. Also, they may 
develop a severe illness if infected by Babesia [9].
MOST COMMON INFECTIONS AND  
RISKS OF COMPLICATIONS
TRAVELLERS’ DIARRhOEA
Travellers’ diarrhoea is the most common travel-acquired 
illness. Usually, it is a self-limiting disease [2]. However, it 
can even be life-threatening to ICTs. The disease may lead 
to bacteraemia, metastatic seeding as well as altered intes-
tinal absorption. Due to changes in the intestinal intake, the 
absorption of oral immunosuppressive agents may also be 
altered [26]. The risk of developing travellers’ diarrhoea is 
definitely higher in transplant patients [5]. This is associated 
with a higher risk of compromised renal function as well 
as increased toxicity of immunosuppressant agents due to 
dehydration [5, 18, 26]. Immunocompromised patients are 
recommended to seek medical assistance if the diarrhoea 
persists for more than 1–2 days and is accompanied with 
fever, vomiting and/or bloody stools. Prophylactic agents 
are rarely recommended for ICTs. If they are prescribed, 
they should only be used for a short period of time. Also, 
immunocompromised patients ought to have a supply of 
antimicrobial agents in case travellers’ diarrhoea occurs. 
The most common drug used as empiric treatment is fluo-
roquinolone. In some cases, azithromycin is also used [26]. 
In her study Hochberg et al. [11] reported of 66.8% of ICTs 
successfully treated with ciprofloxacin and around 30% 
cured with azithromycin. However, it should not be omitted 
that azithromycin may cause a rise in cyclosporine and tac-
rolimus levels, which is especially important in transplant 
recipients. Antimotility agents may delay the clearance of the 
toxins from the intestines. Medications containing bismuth 
may also be prescribed as a therapy; however, it should not 
be forgotten that Supportive Oligonucleotide Technique 
(SOT) recipients with diminished renal function may be at 
an increased risk of salicylate toxicity from bismuth subsa-
licylate metabolism. Taking into account an increased risk 
of water-borne diseases, infections caused by Coccidia, 
giardiasis and microsporidiosis should be considered as 
a potential cause of refractory diarrhoea in ICTs [26].
ARThROPOD-BORNE DISEASES
Vector-borne diseases include those transmitted by 
mosquitoes, sand flies, triatomes and ticks [3]. Malaria and 
dengue are considered the most prevalent travel-related 
arthropod-borne illnesses [27]. Malaria, however, is the 
most common reason of febrile illnesses in travellers [28]. 
There is no evidence that the prevalence of arthropod-borne 
diseases is more common in ICTs than in other groups. 
However, the course of the illness, if acquired, may be more 
severe. This is particularly true for malaria, leishmaniasis 
and Chagas disease [3]. The review cited by Rello et al. [9] 
found that up to 45% of malaria cases in transplant recip-
ients met at least one of the criteria for severe malaria. It 
is also important that malaria may be transmitted with the 
organ from the donor to the recipient, without any history of 
travelling [27]. It was proved that in HIV-positive travellers 
severe malaria occurs more frequently [3]. HIV infection 
may be connected with recurrent malarial parasitaemia, 
more frequent reinfections as well as a more severe course 
of malaria. At the same time, recurrent malaria may lead 
to a decrease in CD4 cell count in HIV-infected travellers, 
also in those under antiretroviral therapy [29]. It is also 
important to highlight that there is a higher risk of severe 
malaria in splenectomised patients due to the impaired 
clearance of intraerythrocytic parasites [5, 9]. All of the 
travellers choosing endemic regions as their travel destina-
tion should receive malaria chemoprophylaxis. Travellers 
with diminished immune response are at a risk of acquiring 
dengue and chikungunya viruses as they are often found 
amongst travellers. There is little evidence of increased 
severity of dengue or chikungunya amongst ICTs [3]. How-
ever, there have been several reports of severe dengue in 
immunocompromised patients [9]. According to Patel et al. 
[3], Chagas disease and leishmaniasis may disseminate in 
immunocompromised patients, especially HIV-infected, as 
well as transplant recipients [3]. Chagas disease, either as 
a reactivation of a latent infection or transmitted from the 
donor organ may be associated with increased mortality [30]. 
PULMONARY DISEASES 
AND SYSTEMIC FUNGAL INFECTIONS
Respiratory tract infections are one of the most common 
travel-related health problems [31]. Of all travellers with 
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medical conditions included in the study by Wieten et al. [4], 
30% suffered from a self-reported respiratory disease. In-
fluenza may be the most prevalent travel-related infection. 
It also increases the risk of pneumonia of bacterial origin, 
especially that caused by S. pneumoniae and S. aureus. 
Every immunocompromised patient should be vaccinated 
with a yearly influenza vaccination, as well as with a pneu-
mococcal vaccination, as this can help reduce the severity of 
symptoms and decrease mortality associated with respirato-
ry infections in immunocompromised patients [2]. According 
to Ericsson [17], HIV-positive patients are at a higher risk 
of acquiring a respiratory tract infection. The risk of Pneu-
mocysitis jirovecii does not seem higher while travelling. As 
Rello et al. [9] estimate, the risk of tuberculosis is elevated 
in immunocompromised patients; however, the risk of the 
travel-acquired tuberculosis has not been determined. The 
risk is connected with the reason to travel. Intense contact 
with local population, inevitable while working in the health 
sector or while VFRs, is associated with a significantly higher 
risk of acquiring tuberculosis. Amongst immunocompro-
mised patients, those with impaired cell-mediated immunity, 
HIV-infected patients as well as those taking TNF-alpha 
blockers, seem to be at an elevated risk of developing tu-
berculosis [5]. It is important to screen these patients for 
latent tuberculosis infection after visiting endemic regions to 
identify the patients at a higher risk of developing active tu-
berculosis [9]. For example, Bhadelia et al. [29] recommend 
that in HIV-positive patients a tuberculin skin test should 
be performed prior to travel and 6 months after return. 
Tuberculosis skin test, however, may have a  decreased 
sensitivity in individuals with impaired cellular immunity [5]. 
Immunocompromised patients are at a  risk of acquiring 
fungal infections, such as for example histoplasmosis, 
coccidioidomycosis and penicilliosis, while travelling [26]. 
These infections are potentially associated with increased 
severity and mortality in immunocompromised patients [9]. 
Sometimes, travel-acquired fungal infections may reveal, 
for example, a HIV infection, as fungal infections are one 
of the most common opportunistic diseases [32]. Fungal 
infections may occur as a  consequence of inhalation or 
skin inoculation and in both cases it may disseminate, due 
to the impaired immunity system. It is crucial to remember 
that a fungal infection acquired while travelling may present 
as an acute infection or as a reactivation many years after 
travelling [33]. Some of these infections may have a long 
incubation period [9]. Due to that fact, a case of potentially 
severe pneumonia, with no confirmed bacteriological cause 
that may be accompanied by dissemination signs such as 
cytopoenia or skin lesions, should make a physician consid-
er a travel-acquired fungal disease as a potential diagnosis 
even long time after travelling [33]. It is important that, as 
Ericsson estimates, some fungi have geographical distribu-
tion so travelling to certain destinations may be connected 
with an increased risk of certain fungal infections, which 
should not be omitted in differential diagnosis. For exam-
ple, travelling to North America and some parts of Central 
and South America may be connected with a higher risk of 
coccidioidomycosis infection. Travelling to Latin America 
may put an immunocompromised traveller at a higher risk 
of acquiring paracoccidioidomycosis and choosing South-
East Asia as a destination may be a  reason to take into 
consideration Penicillum marnefeii as a cause of infection 
in differential diagnosis [17].
SKIN DISEASES
Skin exposure may also be the source of risk. Stron-
gyloides, an insect penetrating intact skin, may lead to 
hyperinfection syndrome in immunosuppressed travellers, 
especially in those under corticosteroidal therapy [3]. It may 
be affiliated with higher mortality in immunocompromised 
patients [9]. However, it is not common in post-transplant pa-
tients due to cyclosporine’s anti-helminthic activity [5]. Also, 
there is a risk of acquiring Leptospirosis after direct skin 
contact with infected rodent urine. The disease may cause 
not only fever but it can also lead to renal and liver failure 
[3]. In immunocompromised patients, it may have a severe 
course and be associated with elevated mortality [32]. 
As mentioned before, fungal infections may occur after skin 
inoculation. It may lead to diverse primary mucosal, cutane-
ous, and subcutaneous infections. In the group of immuno-
compromised patients, lesions may be more extensive than 
in other travellers [33]. As mentioned before, patients under 
anti-TNF treatment are at an elevated risk of developing 
skin infections in general [9]. Transplant recipients are at 
a higher risk of skin cancer, associated with the intensity of 
sun exposure. It is important for these patients to use sun 
protection — hats, sunglasses, protective clothing as well 
as sun-blocking agents with high factors [26].
PREVENTION OF IMMUNOCOMPROMISED 
TRAVELLERS
PRE-TRAVEL CONSULTATION
Allen and Patel highlight that ICTs need specialized 
pre-travel advice in order to address the risks associated 
with travelling. The pre-travel consultation should take place 
several months before potential departure [14]. A structured 
approach should vary depending on a patient’s individual 
immunocompromised state. According to the study amongst 
267 post-transplant patients in the United States and Cana-
da, 37% travelled abroad and 66% sought pre-travel consul-
tation with their transplant doctors. However, despite hav-
ing sought pre-travel advice, only 5% received vaccination 
against hepatitis A before travelling to endemic regions [13]. 
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This shows that specialists need education and guidance on 
pre-travel medical care of immunocompromised patients. 
According to Askling et al. [2], the consultation should by 
performed by a travel medicine specialist in collaboration 
with a relevant specialist. Doctors and specialised clinics 
which take care of immunocompromised patients should 
emphasise the need for pre-travel advice [5]. Interventions 
and guidance should be adequate to each traveller’s  im-
munocompromise state. Patel et al. [3] created a detailed 
check list of pre-travel advice that involve 5 most import-
ant aspects, which obligate a physician to assess travel-
ler’s health, assess the risk of exposure, administer vaccines 
and relevant counselling, administer medical prophylaxis 
and provide medical care and counselling [3].
VACCINATIONS
Before vaccinating an ICT, the physician should take into 
account the mechanism and degree of each patient’s im-
munosuppression. It is essential to choose the type of 
vaccination needed, predict the efficacy of vaccination and 
assess the potential need of revaccination. The destination, 
risk of exposure, duration of travel and activities performed 
while travelling are also very important while considering 
immunization. It must be remembered that the response to 
vaccination and the duration of immunity may vary amongst 
immunocompromised patients, also depending on the type 
of vaccine used [3]. Live vaccines are generally contraindi-
cated in travellers with immune suppression [2, 3]. These 
vaccines may cause vaccine-related disease in patients 
under mild or high immune suppression. If possible, a live 
vaccine should be administered to patients a month before 
the planned beginning of immunosuppressive treatment 
or at least 3 months after the termination of therapy [2]. 
In general, inactivated vaccines are considered safe; how-
ever, their efficacy may vary depending on the immune 
system’s functioning and may not always be fully effective. 
The time of vaccination should also be wisely considered. 
It is important to vaccinate the patient early to achieve full 
immunity before the trip and to allow time to administer 
boosters to the patient if needed [3]. 
In cancer patients, the response to the vaccine is the 
most effective when it is administered prior to chemotherapy 
or radiotherapy or several months after the termination of 
therapy. Hormonal cancer treatments should not affect the 
immunological response to the vaccination [5]. The situa-
tion may vary in transplant recipients. Their immunological 
response to the vaccine may be diminished if an organ 
failure occurred prior to transplantation. The effectiveness 
of the vaccination as well as the duration of immunity may 
be suboptimal, especially during the first 6 months after 
the transplant. When the primary vaccination is performed 
before the transplant and then boosted after it, the response 
to the vaccine seems to be higher. That group of patients 
should be advised, if possible, to get vaccinated at least six 
months after transplantation [5]. Importantly, HBV-specific 
immunity is transferred to the recipient of stem cell trans-
plant if the donor was vaccinated.
In the case of travellers taking corticosteroids and other 
immune suppressive agents, vaccines should be postponed 
one month after the discontinuation of tumour necrosis 
factor inhibitors or corticosteroid therapy [3]. In the case of 
biological treatment, the time after therapy termination may 
be even longer, for example, several months to 1 year [3] or 
6 to 12 months after rituximab therapy [5]. Patel et al. [3] 
highlight that in different situations, if needed, vaccinations 
should be postponed until the immunosuppressants can be 
administered at lower doses or discontinued altogether. In 
HIV-infected patients, there are vaccines that may cause 
a slight elevation in HIV viral load. However, the increase is 
not considered clinically significant [29]. 
As mentioned before, routine vaccinations, including 
annual influenza and pneumococcal vaccination, should 
be offered to that group of travellers [3]. If the patient is 
not a  candidate for vaccination, they should reconsider 
their travel destinations in order to diminish the risk of 
travel-related diseases. According to Patel et al. [3], it is 
especially important while considering travelling to regions 
where live vaccine-preventable diseases are endemic, for 
instance, Sub-Saharan Africa or South America, where the 
risk of yellow fever transmission is high. In the case of 
transplant recipients or those under high-dose immuno-
modulating therapy, these destinations should be avoided 
for at least one year. Travelling to regions with ongoing 
outbreaks should be strongly discouraged in that group of 
travellers in general [3].
MALARIA ChEMOPROPhYLAxIS
All travellers choosing malaria-endemic regions as their 
destination should receive chemoprophylaxis, chosen ac-
cording to the Centres for Disease Control and Prevention 
(CDC) guidelines. For ICTs, it is essential to take possible 
drug interactions into account while choosing the antima-
larial drug regimen. In cancer patients it is important to 
remember that mefloquine may increase the concentration 
of calcineurine inhibitors. At the same time, it is safe for pa-
tients with renal failure, which should be taken into account 
in post-transplant patients. Doxycycline may decrease the 
concentration of mycophenolate [3]. Atovaquone/proguanil 
seems to be safe in the majority of cases; however, the high 
cost of the medication may limit its use. Some antimalarial 
agents, particularly chloroquine, but also mefloquine or 
atovaquone/proguanil, may cause an increase of cyclo-
sporine, sirolimus and tacrolimus concentration. Due to 
that fact, transplant recipients should consider starting 
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malaria chemoprophylaxis several weeks prior to travel in 
order to monitor the concentration of these drugs and find 
an optimal dose of an antimalarial agent [5]. In HIV-infected 
patients it should not be forgotten that antiretroviral medi-
cations, especially protease inhibitor, for example ritonavir, 
may interact with other drugs. Ritonavir may increase the 
concentration of atovaquone. At the same time, atovaquone 
can increase zidovudine concentration. Ritonavir increases 
quinine concentration and it inhibits the metabolism of 
lumefantrine, which is a component of Coartem, an anti-
malarial drug widely used in Africa. There is a higher risk of 
life threatening cardiac arrhythmias in patients taking these 
two drugs simultaneously [5]. Mefloquine may cause a de-
crease in ritonavir concentration. Doxycycline is probably 
safe [22]. Atovaquone/proguanil may be a good choice in 
patients who are under therapy including non-nucleoside 
reverse transcriptase inhibitor. Atovaquone and protease 
inhibitors have limited interactions as well [29].
PREVENTION DURING TRAVELLING
In the study performed by Bialy et al. [34], 65.7% of 
105 ICTs reported behaviours which may have put them 
at a higher risk of infectious diseases. The risk behaviours 
included eating food from unreliable sources or unsafe 
sex practices, also without barrier precautions. Due to this 
fact, it seems highly necessary to provide international 
travellers with full information regarding health and safety 
precautions to be followed while travelling. Food and water 
precautions are particularly important in this group of pa-
tients. Travellers are recommended to drink bottled, boiled 
or filtered water only. Food should be thoroughly cooked 
and eaten immediately after preparation. Undercooked 
meat, fish, seafood and shellfish put a traveller at a risk of 
many viral, bacterial and parasitic infections. Buffet style 
dining should be avoided. Fresh fruits that can be peeled 
seem to be save. Unpasteurised milk products and food 
containing raw eggs may also put a  traveller at a  risk of 
infections [3]. It is essential to use insect repellents contain-
ing diethyltoluamide several times a day in order to avoid 
diseases transmitted by mosquitoes, ticks, sand flies and 
chiggers. It is also advised to wear clothes covering arms 
and legs. Immunocompromised travellers should avoid 
walking barefoot and swimming in freshwater reservoirs 
because of a potentially elevated risk of infecting abrasions 
or transmission of parasitic illnesses, such as the already 
mentioned Strongyloides and Leptospira infections, which 
may lead to severe complications. These patients should 
also avoid caving and outdoors activities to minimise the 
risk of fungal infections [3]. Travellers should remember to 
use barrier precautions during sex. It is essential, especially 
for HIV-infected travellers, not only to reduce the risk of 
transmission of other sexually transmitted infections, but 
also to avoid the acquisition of another HIV strain [17]. 23% 
of HIV-infected travellers studied by Salit et al. [23] reported 
casual sex with new partners while travelling abroad and 
only 58.1% of them confirmed a regular use of condoms. 
The study findings suggest that international travellers have 
little knowledge and awareness of health risk factors and 
health precautions. 
CONCLUSIONS
Given a better quality of life and extended life expectancy 
in patients with immune suppression, the number of ICTs is 
constantly growing. There are some connections between 
this medical condition and travelling. The main areas of 
consideration are the elevated susceptibility to infections, 
various health risks and potentially decreased efficacy of 
vaccinations, but also the issue of drug supply while trav-
elling as well as potential drug interactions. In the group 
of immunocompromised patients, the most common trav-
el-related diseases may be associated with a more severe 
course and more serious complications. Pre-travel counsel-
ling performed by a travel-medicine doctor in collaboration 
with a relevant specialist is essential in ICTs. Interventions 
and guidance should be adequate to each traveller’s immu-
nocompromise state and their general health. Due to that 
fact, every case should be considered individually. 
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